by Laya Kiani | Jul 11, 2024
Intellectual property (IP) rights in regenerative medicine (RM) are crucial for sparking innovation and staying ahead in a competitive market. Protecting inventions through patents and other IP rights encourages investment by giving inventors exclusive market rights....
by Laine Bodnar | Jun 12, 2024
Have you wondered how many cell and gene therapies (CGTs) have been approved in Canada? So did I. To track the number down, I first turned to my trusty internet search engine with hopes that a list of Health Canada-approved CGTs would already exist online. Notably, it...
by Medicine by Design | May 6, 2024
CCRM, the publisher of Signals, has enhanced its long-standing relationship with the University of Toronto’s Medicine by Design through a new strategic alliance. This profile is one in a series of profiles that feature “people” of Medicine by Design. Some minor edits...
by Medicine by Design | Apr 22, 2024
CCRM, the publisher of Signals, has enhanced its long-standing relationship with the University of Toronto’s Medicine by Design through a new strategic alliance. This profile is one in a series of proflies that feature “people” of Medicine by Design. Some minor edits...
by Laine Bodnar | Feb 29, 2024
In my role as a communication professional at CCRM, I have had the opportunity to attend industry conferences and events. There, I have met brilliant minds in the regenerative medicine and cell therapy field and learned about the work that’s happening in their...
Comments